Across TCGA pan-cancer cohorts, DCTN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCTN1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DCTN1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DCTN1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where DCTN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.772	0.352	.011	22	view →
PDAC	OS	Tertile	III,IV	0.977	0.379	.006	16	view →
LUAD	OS	Quartile	III,IV	0.508	0.848	.023	9	view →
HNSC	OS	Quartile	All	0.947	0.798	.025	3	view →
LSCC	DFS	Quartile	III,IV	0.515	0.890	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: DCTN1 tumor-vs-normal RNA expression · all DCTN1 data types